Patent update, page-4

" It is worth noting that the reformation of Idronoxil into a fatty acid/isoflavonoid complex led to Idronoxil being present in the brain in an active form"

Prove it because last time I looked a rat's brain is not human brain. And once again investors were told

"The pre-clinical study, including animal studies involving human brain cancer xenografts, is planned to run for 12 months and if successful to lead in 2018 to a Phase 1 study in combination with TMZ in patients with glioblastoma multiforme." (1 st Feb 2017)
https://www.asx.com.au/asxpdf/20170201/pdf/43fq0bvnkv85l6.pdf

Obvious now being Sept 2019  it was not successful.

Also, the PK trial for healthy patients to test between oral and nox66 delivery of idronxil was unfortunately cancelled or postponed as well.  
https://clinicaltrials.gov/ct2/show/NCT03780465?term=nox66&rank=3

So the examiner I think knows what is real and what is not as it has yet to be proven that the claims are even factually true. There is no data or proof that NOX66 crosses the human BBB and therefore the whole guts of the claim of improved PK to the brain. The claims were made for humans not rats. And even if it did. The examiner is right. So what!!. idronxil is a known chemo sensistiser including brain cancers for years. As he states right at the start the obvious rejections of the claims based on 35 USC 103

No IP since 2012 and yet the hopeful claims keep coming from yourself

"And we can now see that the Targeted Drug Delivery application suggests that Veyonda may have a role in treating brain cancer."